

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 10-Q**

---

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended December 31, 2012

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from            to            .

Commission File Number: 000-50484

---

**MEI Pharma, Inc.**

(Exact name of registrant as specified in its charter)

---

**DELAWARE**  
(State or other jurisdiction of  
incorporation or organization)

**51-0407811**  
(I.R.S. Employer  
Identification No.)

**11975 El Camino Real, Suite 101, San Diego, CA 92130**  
(Address of principal executive offices) (Zip Code)

**(858) 792-6300**  
(Registrant's telephone number, including area code)

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Non-accelerated filer   
Accelerated filer  Smaller reporting entity

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of February 12, 2013, the number of shares outstanding of the issuer's common stock, \$0.00000002 par value, was 15,015,454.

---

---

[Table of Contents](#)

MEI PHARMA, INC.

Table of Contents

	Page	
<b>PART I</b>	<b><a href="#">FINANCIAL INFORMATION</a></b>	
Item 1:	<a href="#">Financial Statements</a>	
	<a href="#">Balance Sheets as of December 31, 2012 (unaudited) and June 30, 2012</a>	3
	<a href="#">Statements of Operations (unaudited) for the three months and six months ended December 31, 2012 and 2011 and for the period from December 1, 2000 (inception) through December 31, 2012</a>	4
	<a href="#">Statements of Cash Flows (unaudited) for the six months ended December 31, 2012 and 2011 and for the period from December 1, 2000 (inception) through December 31, 2012</a>	5
	<a href="#">Notes to Financial Statements (unaudited)</a>	6
Item 2:	<a href="#">Management's Discussion and Analysis of Financial Condition and Results of Operations</a>	12
Item 3:	<a href="#">Quantitative and Qualitative Disclosures about Market Risk</a>	16
Item 4:	<a href="#">Controls and Procedures</a>	16
<b>PART II</b>	<b><a href="#">OTHER INFORMATION</a></b>	
Item 5:	<a href="#">Other Information</a>	18
Item 6:	<a href="#">Exhibits</a>	18
	<a href="#">SIGNATURES</a>	19

**PART I FINANCIAL INFORMATION****Item 1: Financial Statements**

**MEI PHARMA, INC.**  
**(A Development Stage Company)**  
**BALANCE SHEETS**  
**(In thousands, except share and per share data)**

	December 31, 2012 (unaudited)	June 30, 2012
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 26,877	\$ 6,202
Prepaid expenses and other current assets	197	146
Total current assets	27,074	6,348
Property and equipment, net	22	25
Intangible assets, net	488	—
Total assets	<u>\$ 27,584</u>	<u>\$ 6,373</u>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current liabilities:		
Accounts payable	\$ 448	\$ 594
Accrued liabilities	1,349	1,180
Total current liabilities	1,797	1,774
Commitments and contingencies (Note 3)		
Stockholders' equity:		
Preferred stock, \$0.01 par value; 100,000 shares authorized;		
Series A: no shares and 1,000 shares issued and outstanding at December 31, 2012 and June 30, 2012, respectively	—	—
Series B: 742 shares issued and redeemed; none outstanding at December 31, 2012 and June 30, 2012	—	—
Common stock, \$0.00000002 par value; 113,000,000 shares authorized;		
15,015,454 shares and 3,416,491 shares issued and outstanding at December 31, 2012 and June 30, 2012, respectively	—	—
Additional paid-in-capital	116,116	89,710
Deficit accumulated during the development stage	(90,329)	(85,111)
Total stockholders' equity	25,787	4,599
Total liabilities and stockholders' equity	<u>\$ 27,584</u>	<u>\$ 6,373</u>

*See accompanying notes to the unaudited financial statements.*

**MEI PHARMA, INC.**  
**(A Development Stage Company)**  
**STATEMENTS OF OPERATIONS**  
**(In thousands, except share and per share data)**  
**(Unaudited)**

	Three Months Ended December 31,		Six Months Ended December 31,		Period from December 1, 2000 (Inception) through December 31, 2012
	2012	2011	2012	2011	
<b>Operating expenses:</b>					
Research and development	\$ (1,338)	\$ (1,061)	\$ (2,890)	\$ (2,105)	\$ (46,994)
License fees	—	—	—	—	(21,500)
General and administrative	(1,418)	(896)	(2,332)	(1,785)	(25,102)
Total operating expenses	<u>(2,756)</u>	<u>(1,957)</u>	<u>(5,222)</u>	<u>(3,890)</u>	<u>(93,596)</u>
Loss from operations	(2,756)	(1,957)	(5,222)	(3,890)	(93,596)
<b>Other income (expense):</b>					
Fair value of derivative liabilities in excess of proceeds	—	—	—	—	(508)
Adjustments to fair value of derivative liabilities	—	423	—	1,139	1,188
Interest and dividend income	2	2	5	5	2,904
Financing costs	—	(9)	—	(406)	(406)
Gain on sale of investment	—	—	—	—	100
Income tax expense	—	—	(1)	(1)	(11)
Net loss arising during development stage	<u>\$ (2,754)</u>	<u>\$ (1,541)</u>	<u>\$ (5,218)</u>	<u>\$ (3,153)</u>	<u>\$ (90,329)</u>
Net loss per share, basic and diluted	<u>\$ (0.50)</u>	<u>\$ (0.78)</u>	<u>\$ (1.17)</u>	<u>\$ (1.76)</u>	
Shares used to calculate net loss per share	<u>5,455,444</u>	<u>1,979,347</u>	<u>4,477,460</u>	<u>1,788,720</u>	

*See accompanying notes to the unaudited financial statements.*

**MEI PHARMA, INC.**  
**(A Development Stage Company)**  
**STATEMENTS OF CASH FLOWS**  
**(In thousands)**  
**(Unaudited)**

	Six Months Ended December 31,		Period from December 1, 2000 (Inception) through December 31, 2012
	2012	2011	
<b>Cash flows from operating activities:</b>			
Net loss arising during the development stage	\$ (5,218)	\$ (3,153)	\$ (90,329)
Adjustments to reconcile net loss to net cash used in operating activities:			
Share-based compensation	580	256	3,371
Fair value of derivative liabilities in excess of proceeds	—	—	508
Gain on adjustment to fair value of derivative liabilities	—	(1,139)	(1,188)
Financing costs	—	406	406
Depreciation and amortization	19	7	45
Changes in operating assets and liabilities:			
Prepaid expenses and other current assets	(51)	72	(197)
Accounts payable	(146)	53	448
Accrued liabilities	169	(6)	1,349
Net cash used in operating activities	<u>(4,647)</u>	<u>(3,504)</u>	<u>(85,587)</u>
<b>Cash flows from investing activities:</b>			
Purchases of property and equipment	(4)	—	(55)
Net cash used in investing activities	<u>(4)</u>	<u>—</u>	<u>(55)</u>
<b>Cash flows from financing activities:</b>			
Net proceeds from issuance of common stock	25,326	5,043	112,260
Net proceeds from issuance of preferred stock	—	—	665
Financing costs	—	(406)	(406)
Net cash provided by financing activities	<u>25,326</u>	<u>4,637</u>	<u>112,519</u>
Net increase in cash and cash equivalents	20,675	1,133	26,877
Cash and cash equivalents at beginning of the period	6,202	3,858	—
Cash and cash equivalents at end of the period	<u>\$26,877</u>	<u>\$ 4,991</u>	<u>\$ 26,877</u>
<b>Supplemental cash flow information:</b>			
Issuance of common stock for purchase of intellectual property	<u>\$ 500</u>	<u>\$ —</u>	<u>\$ 500</u>

*See accompanying notes to the unaudited financial statements.*

**MEI PHARMA, INC.**  
**(A Development Stage Company)**  
**NOTES TO FINANCIAL STATEMENTS**  
**(Unaudited)**

**1. Organization and Summary of Significant Accounting Policies**

**The Company**

MEI Pharma, Inc. (formerly Marshall Edwards, Inc.), or the Company, is a development stage oncology company focused on the clinical development of novel therapies for cancer. The Company was incorporated in December 2000 as a wholly-owned subsidiary of Novogen Limited (“Novogen”). The Company’s common stock is listed on the Nasdaq Capital Market and was previously listed under the symbol “MSHL” through June 30, 2012. On July 2, 2012, in conjunction with the change in the Company’s corporate name to MEI Pharma, Inc., the Company’s common stock began trading under the symbol “MEIP”. In December 2012, Novogen distributed to its shareholders substantially all of its MEI Pharma common stock. The Company’s former wholly-owned subsidiary, Marshall Edwards Pty Ltd (“MEPL”), was legally dissolved in April 2012. As MEPL was the Company’s only subsidiary, the financial statements are no longer consolidated.

The Company’s business purpose is the development of drugs for the treatment of cancer. The Company is currently focused on the clinical development of its three lead drug candidates, Pracinostat, ME-143 and ME-344. In August 2012, the Company completed the acquisition of certain assets and intellectual property, including those related to Pracinostat, from S\*BIO Pte Ltd, a privately held biotechnology company (“S\*BIO”). In May 2011, the Company completed the acquisition of certain assets and intellectual property, including those related to ME-143 and ME-344, from Novogen, in accordance with the terms of an Asset Purchase Agreement, dated as of December 21, 2010, between the Company, Novogen and Novogen Research Pty Limited. Pracinostat is a selective inhibitor of a group of enzymes called histone deacetylases (HDACs). HDACs belong to a larger set of proteins collectively known as epigenetic regulators that can alter gene expression by chemically modifying DNA or its associated chromosomal proteins. Abnormal activity of these regulators is believed to play an important role in cancer and other diseases. ME-143 and ME-344 are derived from an isoflavone technology platform that has generated a number of compounds with anti-tumor activity. These compounds have been shown to interact with specific targets resulting in the inhibition of tumor metabolism, a function critical for cancer cell survival.

**Basis of Presentation**

The accompanying unaudited financial statements should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended June 30, 2012, included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on September 18, 2012. The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the accompanying financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, the accompanying financial statements reflect all adjustments (consisting of normal recurring adjustments) that are necessary for a fair statement of the financial position, results of operations and cash flows for the interim periods presented. Interim results are not necessarily indicative of results for a full year. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates. The Company has evaluated subsequent events through the date the financial statements were issued.

**Reverse Stock Split**

On December 18, 2012, the Company filed a Certificate of Amendment to its Restated Certificate of Incorporation in order to effect a 1-for-6 reverse stock split (the “2012 Reverse Stock Split”) of the Company’s common stock effective on December 18, 2012. As a result of the 2012 Reverse Stock Split, every six shares of the Company’s issued and outstanding common stock were combined into one share of common stock. The 2012 Reverse Stock Split did not change the number of authorized shares of the Company’s common stock. All financial data and share information in this quarterly report has been presented on an as-adjusted basis to give effect to the 2012 Reverse Stock Split.

## [Table of Contents](#)

### **Use of Estimates**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosures made in the accompanying notes to the consolidated financial statements. The Company uses estimates for certain accruals including clinical and pre-clinical study fees and expenses, share-based compensation, and valuations of derivative liabilities, among others. Actual results could differ from those estimates.

### **Cash and Cash Equivalents**

Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities of three months or less when purchased.

### **Fair Value of Financial Instruments**

The carrying amounts of financial instruments such as cash equivalents and current liabilities approximate the related fair values due to the short-term maturities of these instruments.

### **Concentration of Credit Risk**

Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains accounts in federally insured financial institutions in excess of federally insured limits. However, management believes that the Company is not exposed to significant credit risk due to the financial positions of the depository institutions in which these deposits are held.

### **Property and Equipment**

Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets (generally three to seven years) using the straight-line method. Leasehold improvements are stated at cost and are amortized over the shorter of the estimated useful lives of the assets or the lease term. Capital improvements are stated at cost and amortized over the estimated useful lives of the underlying assets.

### **Intangible Assets**

Intangible assets consist of patents acquired from S\*BIO in August 2012, relating to a family of heterocyclic compounds that inhibit HDACs. Capitalized amounts are amortized on a straight line basis over the expected life of the intellectual property of 14 years. The carrying values of intangible assets are periodically reviewed to determine if the facts and circumstances suggest that a potential impairment may have occurred. Results of operations for the six months ended December 31, 2012 do not reflect any write-downs associated with the potential impairment of intangible assets.

### **Research and Development Costs**

Research and development costs are expensed as incurred and include costs paid to third-party contractors to perform research, conduct clinical trials and develop and manufacture drug materials. Clinical trial costs, including costs associated with third-party contractors, are a significant component of research and development expenses. The Company accrues research and development costs based on work performed. In determining the amount to accrue, management relies on estimates of total costs based on contract components completed, the enrollment of subjects, the completion of trials, and other events.

### **License Fees**

Costs incurred related to the licensing of products that have not yet received regulatory approval to be marketed, or that are not commercially viable and ready for use, or have no alternative future use, are charged to expense in the period incurred.

### **Share-based Compensation**

The fair value of each stock option granted is estimated on the grant date under the fair value method using a binomial valuation model. The estimated fair values of the stock options, including the effect of estimated forfeitures, are expensed over the vesting period. The Company recognized share-based compensation expenses of \$580,000 and \$256,000 during the six months ended December 30, 2012 and 2011, respectively.

### **Interest and Dividend Income**

Interest on cash balances is recognized when earned. Dividend income is recognized when the right to receive the payment is established.

## [Table of Contents](#)

### **Income Taxes**

The Company's income tax expense consists of current and deferred income tax expense or benefit. Current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for the future tax consequences attributable to tax credits and loss carryforwards and to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. As of December 31, 2012 and June 30, 2012, the Company has established a valuation allowance to fully reserve its net deferred tax assets. Tax rate changes are reflected in income during the period such changes are enacted. Changes in ownership may limit the amount of net operating loss carry-forwards that can be utilized in the future to offset taxable income.

The *Financial Accounting Standards Board Topic on Income Taxes* prescribes a recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. An uncertain income tax position will not be recognized if management believes it has less than a 50% likelihood of being sustained. There were no unrecognized tax benefits as of December 31, 2012.

### **2. Net Loss Per Share**

Basic and diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period, less any shares subject to repurchase or forfeiture. There were no shares of common stock subject to repurchase or forfeiture for the three and six months ended December 31, 2012 and 2011. Because the Company is in a net loss position, it has excluded stock options, warrants, and convertible preferred stock from the calculation of diluted net loss per share because these securities are antidilutive for all periods presented. As of December 31, 2012 and 2011, the number of securities excluded from the computation of diluted net loss per share totaled approximately 5,461,800 and 1,399,697, respectively.

### **3. Commitments and Contingencies**

The Company has contracted with various consultants and third parties to assist it in pre-clinical research and development and clinical trials work for its leading drug compounds. The contracts are terminable at any time, but obligate the Company to reimburse the providers for any time or costs incurred through the date of termination. The Company also has employment agreements with certain of its current employees that provide for severance payments and accelerated vesting for share-based awards if their employment is terminated under specified circumstances.

Additionally, the Company leases office space for a monthly rental rate of \$10,734, plus other pass-through charges, under the lease term expiring in April 2013. On January 3, 2013, the Company entered into an amendment to the lease of the Company's office space, which extended the lease term through June 2015, and added additional office space for a new monthly rental rate of \$17,014 to \$18,252 during the term of the amended lease.

#### *Asset Purchase Agreement*

On August 7, 2012, the Company entered into a definitive asset purchase agreement with S\*BIO, pursuant to which the Company agreed to acquire certain assets comprised of intellectual property and technology including rights to Pracinostat, an HDAC inhibitor in Phase II clinical trials for hematologic cancers, from S\*BIO in exchange for \$500,000 of common stock. The agreement also provides for potential success-based clinical, regulatory and sales milestone payments of up to \$75.2 million, as well as contingent earn-out payments based on net sales.

#### *License Agreement*

On September 28, 2012, the Company entered into a license agreement with CyDex Pharmaceuticals, Inc. ("CyDex"). Under the license agreement, CyDex granted to the Company an exclusive, nontransferable license to intellectual property rights relating to Captisol<sup>®</sup> for use with the Company's two lead isoflavone-based drug compounds. The Company agreed to pay to CyDex a non-refundable license issuance fee, future milestone payments, and royalties on future sales of the Company's approved drugs utilizing Captisol. Contemporaneously with the license agreement, the Company and CyDex entered into a commercial supply agreement pursuant to which the Company agreed to purchase 100% of its requirements for Captisol from CyDex. The Company may terminate both the license agreement and the supply agreement for convenience at any time upon 90 days' prior written notice.



#### **4. Segment Information**

The Company has one operating segment, the development of pharmaceutical compounds. The Company's business contained two geographic segments, the United States of America and Australia, from inception until MEPL's legal dissolution in April 2012. For the three and six months ended December 31, 2011, net losses attributable to Australia were immaterial. All of the Company's assets and liabilities were located in the United States of America as of December 31, 2012 and June 30, 2012.

#### **5. Related Party Transactions**

In March 2012, the Company distributed one subscription right for each share of common stock and each Series A warrant exercisable for a share of common stock to holders of record as of March 30, 2012. Each subscription right entitled the holder to purchase one Unit, which consisted of 0.0833 shares of the Company's common stock and a warrant representing the right to purchase 0.04167 shares of the Company's common stock. In connection with the rights offering, in May 2012, Novogen purchased 1,498,112 units consisting of 749,056 shares of common stock and warrants to purchase an additional 374,528 shares of common stock. The warrants are exercisable for a five-year period beginning on May 11, 2012, at an exercise price of \$7.14 per share. See further discussion regarding the Rights Offering in Note 6 "Stockholders' Equity".

On September 27, 2011, the Company entered into a Securities Subscription Agreement with Novogen, pursuant to which the Company sold to Novogen 222,222 shares of common stock, at a purchase price of \$9.00 per share, for proceeds of \$2,000,000. The offering closed on September 29, 2011. On December 28, 2011, the Company entered into a Securities Subscription Agreement with Novogen, pursuant to which the Company sold to Novogen 323,624 shares of common stock, at a purchase price of \$6.18 per share, for proceeds of \$2,000,000. The offering closed on December 29, 2011.

Novogen was the majority shareholder from the Company's inception through December 3, 2012. On such date, Novogen completed the distribution of substantially all of its MEI Pharma common stock to its shareholders. Historically, the Company licensed from Novogen the rights to Novogen patents and applications for the Company's lead isoflavone-based drug candidates, as well as other compounds. Additionally, Novogen historically provided research and development services and administrative and finance services to the Company under service agreements. The license agreements were terminated in May 2011, in conjunction with the Company's purchase of a portfolio of isoflavone-related assets from Novogen, which the Company refers to as the "Isoflavone Transaction". The service agreements were terminated in December 2010.

On December 5, 2012, the Company entered into an agreement (the "Waiver Agreement") with Novogen and Novogen Research Pty Limited, a wholly-owned subsidiary of Novogen (together, the "Novogen Parties"), Graham Kelly, an individual ("Kelly"), and Andrew Heaton, an individual ("Heaton"), pursuant to which the Company granted a limited waiver with respect to certain non-compete provisions contained in the Asset Purchase Agreement dated as of December 20, 2010, between the Company and the Novogen Parties. In consideration of the Company's grant of the limited waiver, upon the execution of the Waiver Agreement, Novogen surrendered to the Company for cancellation warrants held by Novogen for the purchase of 166,666 shares of Common Stock.

#### **6. Stockholders' Equity**

##### **Equity Transactions**

###### *Private Placement*

On December 18, 2012, the Company completed the sale (the "December 2012 private placement") of 9,166,665 shares of common stock and warrants to purchase an additional 6,416,665 shares of common stock for an aggregate offering price of \$27.5 million, pursuant to the terms of the previously announced Securities Purchase Agreement, dated November 4, 2012, between the Company and certain accredited investors identified therein.

###### *Asset Purchase*

On August 7, 2012, the Company entered into a definitive asset purchase agreement with S\*BIO Pte Ltd ("S\*Bio"), a privately held biotechnology company, pursuant to which the Company agreed to acquire certain assets comprised of intellectual property and technology including rights to Pracinostat, a histone deacetylases (HDAC) inhibitor in Phase II clinical trials for hematologic cancers, from S\*BIO in exchange for \$500,000 of common stock. The agreement also provides for potential success-based clinical, regulatory and sales milestone payments of up to \$75.2 million, as well as contingent earn-out payments based on net sales. The Company may pay up to \$500,000 of the first milestone payment in shares of common stock. On August 22, 2012, the Company completed the asset purchase and issued 195,756 shares of common stock to S\*BIO.

## [Table of Contents](#)

### *Rights Offering*

On March 26, 2012, the Company's registration statement on Form S-1, as previously filed with the Securities and Exchange Commission on February 21, 2012 and amended on March 20, 2012, became effective. The Form S-1 was filed in connection with the Company's rights offering ("Rights Offering") to existing stockholders and to holders of the Company's Series A warrants issued in connection with the May 2011 private placement. Pursuant to the Rights Offering, the Company distributed one subscription right for each share of common stock and each Series A warrant exercisable for a share of common stock to holders of record as of March 30, 2012. Each subscription right entitled the holder to purchase one Unit, which consisted of 0.0833 shares of the Company's common stock and a warrant to purchase 0.04167 shares of the Company's common stock. The subscription period expired on May 11, 2012. The Rights Offering also included an over-subscription privilege, which entitled stockholders to purchase additional Units that remained unsubscribed at the expiration of the Rights Offering. For every two Units purchased in the Rights Offering, stockholders received 0.1667 share of common stock for a purchase price of \$5.34 per whole share, which represented a 10 percent discount to the volume-weighted average price of the Company's common stock for the 30 consecutive trading days ending on, and inclusive of, March 13, 2012, and warrants to purchase 0.0833 share of common stock with an exercise price of \$7.14 per whole share, which represented a 20 percent premium to the volume-weighted average price of the Company's common stock during the same period. The warrants are exercisable for a five-year period beginning on May 11, 2012. The Company issued 971,700 shares of common stock and warrants to purchase an additional 485,859 shares of common stock in conjunction with the Rights Offering. Net proceeds associated with the Rights Offering were \$4.8 million.

### **Warrants and Options to Purchase Common Stock**

During December 2012, 1,777,604 warrants that had been issued in the Company's December 2012 private placement were exercised on a cashless basis, pursuant to which the Company issued 1,312,883 shares of common stock upon exercise of the warrants. Additionally, during December 2012, 194,381 warrants that had been issued in the Company's May 2011 private placement were exercised on a cashless basis, pursuant to which the Company issued 119,158 shares of common stock upon exercise of the warrants.

As of December 31, 2012, there were outstanding (i) warrants issued in the Company's December 2012 private placement that are exercisable to purchase 4,639,061 shares of the Company's common stock at an exercise price of \$3.12, which expire in December 2017; (ii) warrants issued in conjunction with the Rights Offering that are exercisable to purchase 319,191 shares of the Company's common stock at an exercise price of \$7.14 per share, which expire in May 2017; (iii) Series A warrants issued in the Company's May 2011 private placement that are exercisable to purchase 215,721 shares of common stock at an exercise price of \$6.00 per share, which expire in November 2016; and (iv) other outstanding warrants that are exercisable to purchase 768 shares of the Company's common stock at an exercise price of \$130.20 per share, which expire in July 2013.

As of December 31, 2012 there were options outstanding to purchase 287,059 shares of common stock at exercise prices ranging from \$2.76 to \$37.80 per share. The outstanding options expire at various dates in calendar years 2014 through 2017.

The fair value of each stock option granted is estimated on the grant date under the fair value method using a binomial valuation model. The estimated fair values of the stock options, including the effect of estimated forfeitures, are expensed over the vesting period. To calculate these fair values, the following assumptions were used:

	Six months ended December 31,	
	2012	2011
Risk-free interest rate	.62% - .78%	.90% - 1.32%
Expected life	5 years	5 years
Expected volatility	153% - 161%	145% - 148%
Dividend yield	0%	0%
Weighted-average grant date fair value	\$ 4.47	\$ 8.58

Stock option activity for the six months ended December 31, 2012 was as follows:

	Stock options outstanding	Weighted average exercise price	Weighted average remaining contractual term (years)	Aggregate intrinsic value
Outstanding at June 30, 2012	143,926	\$ 11.64	3.0	\$ —
Options granted	143,133	\$ 4.98	4.7	\$ —
Options forfeited or expired	—	\$ 0.00	—	\$ —
Outstanding at December 31, 2012	287,059	\$ 8.32	3.9	\$ —
Exercisable at December 31, 2012	120,948	\$ 11.02	3.7	\$ —

Unrecognized compensation expense related to non-vested stock options totaled \$433,000 as of December 31, 2012. Such compensation expense is expected to be recognized over a weighted-average period of 2.8 years.

**Series A Convertible Preferred Stock**

In connection with the closing of the Isoflavone Transaction in May 2011, the Company issued to Novogen 1,000 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock"). Each share of Series A Preferred Stock was initially convertible into 804.5 shares of common stock. In addition, if a Phase II clinical trial involving the Company's isoflavone technology were to achieve a statistically significant result ( $p=0.05$  or less) or a first patient were enrolled in a Phase III clinical trial using the Company's isoflavone technology, then any share of the Series A Preferred Stock not already converted may thereafter have been converted into 1,609 shares of common stock. On November 19, 2012, Novogen provided the Company written notice of conversion with respect to all of the 1,000 shares of Series A Preferred Stock held by Novogen. In accordance with the terms of the Preferred Shares, on November 20, 2012, the Company issued to Novogen 804,500 shares of common stock. As described above, in December 2012, Novogen completed a capital reduction and in specie distribution to the Novogen shareholders of substantially all of the shares of the Company's common stock that it owned.

## Item 2: Management's Discussion and Analysis of Financial Condition and Results of Operations

### Special Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding the future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things:

- our inability to obtain required additional financing or financing available to us on acceptable terms, or at all, which may cause us to delay, scale-back or eliminate plans related to development of our drug candidates;
- we are in an early stage of clinical studies for our product candidates on which our development plans are based; clinical studies by their nature typically have a high level of risk and may not produce successful results;
- the results of pre-clinical studies and completed clinical trials are not necessarily predictive of future results, and our current drug candidates may not have favorable results in later studies or trials;
- our inability to maintain or enter into, and the risks resulting from our dependence upon, contractual arrangements necessary for the clinical development, manufacture, commercialization, marketing, sales and distribution of our product candidates;
- costs and delays in the clinical development programs and/or receipt of U.S. Food and Drug Administration (the "FDA") or other required governmental approvals, or the failure to obtain such approvals, for our product candidates;
- our failure to successfully commercialize our product candidates;
- the failure of any products to gain market acceptance;
- our inability to control the costs of manufacturing our products;
- competition and competitive factors;
- our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business;
- our inability to operate our business without infringing the patents and proprietary rights of others;
- costs stemming from our defense against third party intellectual property infringement claims;
- general economic conditions;
- technological changes;
- government regulation generally and the receipt of regulatory approvals;
- changes in industry practice; and
- one-time events.

These risks are not exhaustive. Our business and financial performance could also be adversely affected by the factors that are discussed under "Risk Factors" in the Annual Report on Form 10-K for the year ended June 30, 2012, filed on September 18, 2012, as well as factors discussed elsewhere in this report and in our other filings with the Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for us to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

You should not rely upon forward looking statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward looking statements will be achieved or occur. Although we believe that the expectations reflected in the forward looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

The following discussion is qualified in its entirety by, and should be read in conjunction with, the more detailed information set forth in the financial statements and the notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q.

### Overview

MEI Pharma, Inc. (formerly Marshall Edwards Inc.) is a development-stage oncology company focused on the clinical development of novel small molecules for the treatment of cancer. We were incorporated in Delaware in 2000 as a wholly owned subsidiary of Novogen Limited ("Novogen"). Our common stock is listed on the Nasdaq Capital Market and was previously listed

## [Table of Contents](#)

under the symbol “MSHL” through June 30, 2012. On July 2, 2012, in conjunction with the change of our corporate name to MEI Pharma, Inc., our common stock began trading under the symbol “MEIP”. In December 2012, Novogen distributed to its shareholders substantially all of its MEI Pharma common stock.

Our business purpose is the development of drugs for the treatment of cancer. We are currently focused on the clinical development of our three lead drug candidates, Pracinostat, ME-143 and ME-344. Pracinostat has been tested in more than 150 patients in multiple Phase I and exploratory Phase II clinical trials, including advanced hematologic malignancies such as myelodysplastic syndrome (MDS), acute myeloid leukemia and myelofibrosis. We expect to initiate a randomized, placebo-controlled Phase II trial of Pracinostat in combination with azacitidine in patients with MDS during the second quarter of calendar year 2013. Results from a Phase I clinical trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing. In May 2011, we completed the acquisition of certain assets and intellectual property, including those related to ME-143 and ME-344, from Novogen, in accordance with the terms of an Asset Purchase Agreement, dated as of December 21, 2010, between us, Novogen and Novogen Research Pty Limited. In August 2012, we completed the acquisition of certain assets and intellectual property, including those related to Pracinostat, from S\*BIO Pte Ltd (“S\*BIO”).

### **Relationship with Novogen**

Novogen was our majority shareholder from our inception through December 3, 2012. On such date, Novogen completed the distribution of substantially all of its MEI Pharma common stock to its shareholders. Historically, we licensed from Novogen the rights to Novogen patents and applications for our lead isoflavone-based drug candidates, as well as other compounds. Additionally, Novogen historically provided research and development services and administrative and finance services to us under service agreements. Our license agreements with Novogen were terminated in May 2011 in conjunction with our purchase of a portfolio of isoflavone-related assets from Novogen, which we refer to as the “Isoflavone Transaction”. The service agreements with Novogen were terminated in December 2010.

### **Critical Accounting Policies and Estimates**

Management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and related disclosures. Actual results could differ from those estimates. We believe the following accounting policies to be critical to the judgments and estimates used in the preparation of our financial statements.

#### *Clinical Trials Expenses and Accruals*

Estimates have been used in determining the expense and accrued liability under certain clinical trial contracts where services have been performed but not yet invoiced. Generally, the costs associated with clinical trial contracts are based on the number of patients in each trial, the service contracts associated with clinical sites, service providers and drug development contracts. The length of time before actual amounts can be determined will vary, and are therefore estimated, depending on length of the drug administration cycles and the timing of the invoices by the clinical trial partners and contractors.

#### *Share-based Compensation*

Share-based compensation expense for employees and directors is recognized in the statement of operations based on estimated amounts, including the grant date fair value and the expected service period. For stock options, we estimate the grant date fair value using a binomial valuation model, which requires the use of multiple subjective inputs including estimated future volatility, expected forfeitures and the expected term of the awards. We estimate our expected future volatility based on our stock’s historical price volatility. Our stock’s future volatility may differ from our estimated volatility at the grant date. Share-based compensation recorded in our statement of operations is based on awards expected to ultimately vest and has been reduced for estimated forfeitures. Our estimated forfeiture rates may differ from actual forfeiture rates which would affect the amount of expense recognized during the period. We recognize the value of the awards on a straight-line basis over the awards’ requisite service periods. The requisite service period is generally the time over which our share-based awards vest.

### **Results of Operations**

#### **Three Months Ended December 31, 2012 and 2011**

We incurred losses of \$2,754,000 and \$1,541,000 for the three months ended December 31, 2012 and 2011, respectively.

**Research and Development:** Research and development expenses consist primarily of clinical trial costs (including payments to contract research organizations or CROs), pre-clinical study costs, cost to manufacture our drug candidates for pre-clinical and clinical studies and salaries and other personnel costs. Research and development expenses increased by \$277,000 to \$1,338,000 for the three months ended December 31, 2012 compared to \$1,061,000 for the three months ended December 31, 2011. The increase is primarily due to costs associated with Phase I clinical trial costs and drug manufacturing costs for ME-143 and ME-344.

## [Table of Contents](#)

**General and Administrative:** General and administrative expenses increased by \$522,000 to \$1,418,000 for the three months ended December 31, 2012 compared to \$896,000 for the three months ended December 31, 2011. The increase primarily relates to professional and consulting expenses, and stock-based compensation expenses.

**Other income or expense:** We received interest on cash and cash equivalents of \$2,000 for the three months ended December 31, 2012 and \$2,000 for the three months ended December 31, 2011. Additionally, during the year ended June 30, 2011, we issued securities that were accounted for as derivative liabilities. As of December 31, 2011, our obligations related to these securities were contractually completed, resulting in the elimination of the derivative liabilities and a corresponding net decrease in their value of \$423,000 during the three months ended December 31, 2011, which was recorded as non-operating income.

### **Six Months Ended December 31, 2012 and 2011**

We incurred losses of \$5,218,000 and \$3,153,000 for the six months ended December 31, 2012 and 2011, respectively.

**Research and Development:** Research and development expenses consist primarily of clinical trial costs (including payments to CROs), pre-clinical study costs, cost to manufacture our drug candidates for pre-clinical and clinical studies and salaries and other personnel costs. Research and development expenses increased by \$785,000 to \$2,890,000 for the six months ended December 31, 2012, compared to \$2,105,000 for the six months ended December 31, 2011. The increase is primarily due to costs associated with Phase I clinical trial costs and drug manufacturing costs for ME-143 and ME-344.

**General and Administrative:** General and administrative expenses increased by \$547,000 to \$2,332,000 for the six months ended December 31, 2012 compared to \$1,785,000 for the six months ended December 31, 2011. The increase primarily relates to legal fees and other costs associated with the issuance of common stock to S\*Bio in conjunction with the purchase of Pracinostat, professional and consulting expenses, and stock-based compensation expenses.

**Other income or expense:** We received interest on cash and cash equivalents of \$5,000 for the six months ended December 31, 2012 and \$5,000 for the six months ended December 31, 2011. Additionally, during the year ended June 30, 2011, we issued securities that were accounted for as derivative liabilities. As of December 31, 2011, our obligations related to these securities were contractually completed, resulting in the elimination of the derivative liabilities and a corresponding net decrease in their value of \$1,125,000 during the six months ended December 31, 2011, which was recorded as non-operating income. Additionally, during the six months ended December 31, 2011, we recorded a reversal of a prior expense of \$14,000 in conjunction with amending the Series A Warrant terms pursuant to the Supplemental Agreement, based on the fair value of the Amended Series A Warrants. In connection with the Supplemental Agreement, we incurred financing costs in the amount of \$406,000 during the six months ended December 31, 2011.

### **Liquidity and Capital Resources**

Our sources of liquidity include our cash and cash equivalents. Our existing cash balances were approximately \$26.9 million as of December 31, 2012. Our current business operations are focused on continuing the clinical development of our three lead drug candidates, Pracinostat, ME-143 and ME-344. Changes to our research and development plans or other changes affecting our operating expenses may affect actual future use of existing cash resources. To date, we have obtained cash and funded our operations primarily through the sale of equity securities. We have accumulated losses of \$90.3 million since inception and expect to incur operating losses and generate negative cash flows from operations for the foreseeable future. In order to continue the development of our lead drug candidates, at some point in the future we may pursue one or more capital transactions, whether through the sale of equity securities or entry into strategic partnerships.

#### *Sources and Uses of Our Cash*

Net cash used in operations for the six months ended December 30, 2012 was \$4,647,000 compared to \$3,504,000 in the six months ended December 31, 2011, due to our net loss resulting from expenses incurred for research and development and general and administrative costs.

Net cash provided by financing activities was \$25,326,000 during the six months ended December 31, 2012. Cash raised during the six months ended December 31, 2012 reflected net proceeds of \$25,326,000 raised through the issuance of common stock and warrants in our "December 2012 private placement. Net cash provided by financing activities was \$4,637,000 during the six months ended December 31, 2011. Cash raised during the six months ended December 31, 2011 reflected net proceeds of \$1,094,000 raised through the issuance of common stock from the exercise of Series B warrants and \$3,949,000 through the issuance of common stock to Novogen. Additionally, during the six months ended December 31, 2011, we paid \$406,000 in financing costs associated with amending the terms of securities that had been issued as part of the May 2011 private placement.

## [Table of Contents](#)

### ***Contractual Obligations***

We have contracted with various consultants and third parties to assist us in pre-clinical research and development and clinical trials work for our leading drug compounds. The contracts are terminable at any time, but obligate us to reimburse the providers for any time or costs incurred through the date of termination. Additionally, we have employment agreements with certain of our current employees that provide for severance payments and accelerated vesting for share-based awards if their employment is terminated under specified circumstances.

In July 2010, we entered into a lease arrangement to rent approximately 3,676 square feet of office space for 33 months beginning in July 2010 for monthly rental rates ranging from \$10,109 to \$10,734 over the lease term, plus other pass-through charges. On January 3, 2013, we entered into an amendment to the lease (“First Lease Amendment”). The First Lease Amendment extends the lease term through June 2015. In addition, it adds expansion space of approximately 2,511 square feet of office space, which co-terminates with the extension of the original lease in June 2015. The additional expansion space portion of the lease begins on the later of February 1, 2013 or upon the completion of certain improvements to be performed by the landlord. Once both the original space extension and the expansion space portion of the lease become effective, we will lease approximately 6,187 square feet of space at a monthly rental rate of \$17,014 to \$18,252 during the term of the lease.

### ***License Agreement***

On September 28, 2012, we entered into a license agreement with CyDex Pharmaceuticals, Inc. (“CyDex”). Under the license agreement, CyDex granted to us an exclusive, nontransferable license to intellectual property rights relating to Captisol® for use with our two lead isoflavone-based drug compounds. We agreed to pay to CyDex a non-refundable license issuance fee, future milestone payments, and royalties on future sales. Contemporaneously with the license agreement, we entered into a commercial supply agreement with Cydex pursuant to which we agreed to purchase 100% of its requirements for Captisol from CyDex. We may terminate both the license agreement and the supply agreement for convenience at any time upon 90 days’ prior written notice.

### **Corporate Developments**

#### ***December 2012 Private Placement***

On December 18, 2012, we completed the sale (the “December 2012 private placement”) of 9,166,665 shares (the “Initial Shares”) of common stock and warrants (the “Warrants”) to purchase an additional 6,416,665 shares (the “Warrant Shares” and, together with the Initial Shares, the “Shares”) of common stock for an aggregate offering price of \$27.5 million, pursuant to the terms a Securities Purchase Agreement, dated November 4, 2012, between us and certain accredited investors identified therein. As a result of the December 2012 private placement, two of the investors, Vivo Ventures Fund VII, L.P. (“Vivo”) and New Leaf Ventures II, L.P. (“New Leaf”) own in excess of 20% of our outstanding common stock.

We have entered into a separate governance agreement with each of Vivo and New Leaf pursuant to which each of them is entitled to propose a candidate for election to our board of directors for consideration by the nominating committee of the board of directors in connection with each annual meeting of our stockholders following the effectiveness of an amended and restated certificate of incorporation eliminating our classified board of directors, and at such other times as such investor may propose. We have agreed to use our best efforts to cause the board of directors to elect one of the candidates proposed by Vivo or New Leaf to serve as Chairman of the board of directors and to cause the board of directors to appoint at least one of any such candidates serving on the board of directors to serve on each standing and special committee of the board of directors. All candidates proposed by Vivo and New Leaf will be presented to the nominating committee for the same consideration as individuals identified by the nominating committee through other means. Each governance agreement will terminate with respect to the applicable investor at the earliest of (i) such time as such investor and its affiliates beneficially owns all of the shares of common stock then outstanding, (ii) such time as such investor and its affiliates beneficially own less than 10% of the shares of common stock then outstanding, or (iii) the effectiveness of certain change of control transactions resulting in continuing stockholders of the Company holding less than 50% of the outstanding voting securities of the Company, its successor entity or a parent or subsidiary of its successor entity. On February 7, 2013, the Board appointed Thomas C. Reynolds, M.D., Ph.D., to fill the vacancy created by the expansion of the size of the Board from six members to seven members that became effective on December 18, 2012. Dr. Reynolds was proposed to the nominating committee of the board of directors pursuant to the terms of the governance agreements. On January 27, 2013, Professor Williams notified the Company of his decision not to stand for re-election to the board of directors at the Company’s Annual Meeting to be held on March 26, 2013. As a result, the Company has commenced a search process to fill the vacancy created by Professor Williams’s retirement from the board of directors. It is expected that at a future date, a candidate proposed under the governance agreements will be considered by the nominating committee of the board of directors to fill the vacancy that will be created upon Professor Williams’s retirement from the board of directors.

### ***Waiver Agreement***

On December 5, 2012, we entered into an agreement (the “Waiver Agreement”) with Novogen and Novogen Research Pty Limited, a wholly-owned subsidiary of Novogen (together, the “Novogen Parties”), Graham Kelly, an individual (“Kelly”), and Andrew Heaton, an individual (“Heaton”), pursuant to which we granted a limited waiver with respect to certain non-compete provisions contained in the Asset Purchase Agreement dated as of December 20, 2010, between us and the Novogen Parties. In consideration of our grant of the limited waiver, upon the execution of the Waiver Agreement, Novogen surrendered to us for cancellation warrants held by Novogen for the purchase of 166,666 shares of common stock, as adjusted for the 2012 Reverse Stock Split described below.

## [Table of Contents](#)

### *Reverse Stock Split*

On December 18, 2012, we filed a Certificate of Amendment to our Restated Certificate of Incorporation in order to effect a 1-for-6 reverse stock split (the “2012 Reverse Stock Split”) of our common stock effective on December 18, 2012. As a result of the 2012 Reverse Stock Split, every six shares of our issued and outstanding common stock were combined into one share of common stock. The 2012 Reverse Stock Split did not change the number of authorized shares of common stock. All financial data and share information in this quarterly report has been presented on an as-adjusted basis to give effect to the 2012 Reverse Stock Split.

### *NASDAQ*

On March 27, 2012, we received notice from NASDAQ stating that, based on the closing bid price for our common stock for the last 30 consecutive business days, we no longer met the \$1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market under Nasdaq Rule 5550(a)(2). The notification letter stated that we would be afforded a grace period of 180 calendar days, or until September 24, 2012, to regain compliance with the minimum bid price requirement in accordance with Nasdaq Rule 5810(c)(3)(A). In order to regain compliance, shares of our common stock must maintain a minimum closing bid price of at least \$1.00 per share for a minimum of ten consecutive business days during the grace period. On September 25, 2012, we received a determination letter from NASDAQ notifying us that we had not regained compliance with the Rule during the 180 calendar day period and that our common stock was therefore subject to delisting from The Nasdaq Capital Market, unless we requested a hearing before the NASDAQ Listing Qualifications Panel (the “Panel”). On October 2, 2012, we timely requested a hearing before the Panel to present our plan to regain compliance with from compliance with Nasdaq Rule 5550(a)(2), which request automatically stayed the delisting of our securities pending at least the issuance of the Panel’s decision following the hearing, which was held on November 1, 2012. On November 8, 2012, we were notified by the Panel that it granted our request for continued listing subject to the condition that on or before February 11, 2013, we shall have evidenced a closing bid price of \$1.00 or more for a minimum of ten prior consecutive trading days. On November 26, 2012, we received notice from NASDAQ stating that we had regained compliance with the applicable minimum bid price rule, as required by the Panel’s decision on November 8, 2012, and that we were in compliance with all other applicable requirements set forth in the Panel’s decision and required for listing on the Nasdaq Capital Market. Accordingly, the Panel determined to continue the listing of the Company’s securities on The Nasdaq Stock Market and closed the matter.

### *Recent Accounting Pronouncements*

See Item 1 of Part I, “Notes to Financial Statements- Note 1- Organization and Summary of Significant Accounting Policies”.

## **Item 3: Quantitative and Qualitative Disclosures about Market Risk**

### **Interest Rate Risk**

Our exposure to market interest rates relates primarily to the investments of cash balances. We have cash reserves held primarily in U.S. dollars and we place funds on deposit with financial institutions and are generally at call.

We do not use derivative financial instruments to hedge our risks related to cash balances. We place our cash deposits with high credit quality financial institutions, and, by policy, limit the amount of credit exposure to any single counter-party. We are adverse to principal loss and we ensure the safety and preservation of our invested funds by limiting default risk, market risk and reinvestment risk. We seek to mitigate default risk by depositing funds with high credit quality financial institutions and by constantly positioning its portfolio to respond appropriately to a significant reduction in a credit rating of any financial institution.

We do not consider the effects of interest rate movements to be a material risk to our financial condition.

## **Item 4: Controls and Procedures**

### **Evaluation of Disclosure Controls and Procedures**

At the end of the period covered by this Quarterly Report on Form 10-Q, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be



---

## [Table of Contents](#)

disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective to ensure that the information required to be disclosed by the Company in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms.

There were no changes in our internal control over financial reporting during the period covered by this Quarterly Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**PART II OTHER INFORMATION**

**Item 5. Other Information**

Please see the discussion of the separate governance agreements entered into on December 18, 2012 between the Company and each of Vivo and New Leaf that appears in this report under Item 2. Management's Discussion and Analysis of Results of Operations and Financial Condition—Corporate Developments—December 2012 Private Placement, which discussion is incorporated herein by reference.

**Item 6: Exhibits**

**Exhibit Index**

Exhibits

4.1	Form of Warrant (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on November 5, 2012 (File No. 000-50484)).
10.1	Securities Purchase Agreement, dated as of November 4, 2012, by and among the Company, Vivo Ventures Fund VII, L.P., Vivo Ventures VII Affiliates Fund, L.P., and New Leaf Ventures II, L.P., and certain other accredited investors identified in Exhibit A thereto (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on November 5, 2012 (File No. 000-50484)).
10.2	Form of Governance Agreement between the Company and Vivo Ventures and New Leaf Venture Partners (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed on November 5, 2012 (File No. 000-50484)).
10.3	Form of Registration Rights Agreement between the Company and Vivo Ventures and New Leaf Ventures II, L.P. (incorporated by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K filed on November 5, 2012 (File No. 000-50484)).
31.1	Rule 13a-14(a) or Rule 15d-14(a) Certification of Principal Executive Officer
31.2	Rule 13a-14(a) or Rule 15d-14(a) Certification of Principal Financial Officer
32.1	Certification of Principal Executive Officer and Principal Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) and section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C 1350).
101.INS	XBRL Instance Document.
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Quarterly Report to be signed on its behalf by the undersigned, thereunto duly authorized.

MEI Pharma, Inc.

/s/ Daniel P. Gold

Daniel Gold

President and Chief Executive Officer

Date: February 12, 2013

## CERTIFICATION

I, Daniel Gold, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of MEI Pharma, Inc.;
2. Based on my knowledge, this Quarterly Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Quarterly Report;
3. Based on my knowledge, the financial statements, and other financial information included in this Quarterly Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Quarterly Report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Quarterly Report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in the Quarterly Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Quarterly Report based on such evaluation; and
  - (d) Disclosed in this Quarterly Report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors:
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 12, 2013

/s/ Daniel Gold

Daniel Gold  
President and Chief Executive Officer  
(Principal Executive Officer)

**CERTIFICATION**

I, Thomas M. Zech, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of MEI Pharma, Inc.;
2. Based on my knowledge, this Quarterly Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Quarterly Report;
3. Based on my knowledge, the financial statements, and other financial information included in this Quarterly Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Quarterly Report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) ) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Quarterly Report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in the Quarterly Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Quarterly Report based on such evaluation; and
  - (d) Disclosed in this Quarterly Report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
5. The Company's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors:
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 12, 2013

/s/ Thomas M. Zech

Thomas M. Zech  
Chief Financial Officer  
(Principal Financial Officer)

## CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934, as amended, and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), Daniel P. Gold, the President and Chief Executive Officer of MEI Pharma, Inc. (the "Registrant"), and Thomas M. Zech, the Chief Financial Officer of the Registrant, each hereby certifies that, to his knowledge:

1. The Registrant's Quarterly Report on Form 10-Q for the period ended December 31, 2012, (the "Form 10-Q") to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition of the Registrant at the end of the period covered by the Form 10-Q and results of operations of the registrant for the period covered by the Form 10-Q.

These certifications accompanying the Form 10-Q to which they relate, are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

Dated: February 12, 2013

/s/ Daniel P. Gold

\_\_\_\_\_  
Daniel P. Gold  
President and Chief Executive Officer  
(Principal Executive Officer)

/s/ Thomas M. Zech

\_\_\_\_\_  
Thomas M. Zech  
Chief Financial Officer  
(Principal Financial Officer)